148775-23-9

Basic information

• Product Name: (2E)-3-(2,4-dichlorophenyl)prop-2-en-1-ol
• Synonyms: (2E)-3-(2,4-dichlorophenyl)prop-2-en-1-ol
• CAS NO: 148775-23-9
• Molecular Weight: 203.068
• Mol File: 148775-23-9.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: (2E)-3-(2,4-dichlorophenyl)prop-2-en-1-ol(CAS DataBase Reference)
• NIST Chemistry Reference: (2E)-3-(2,4-dichlorophenyl)prop-2-en-1-ol(148775-23-9)
• EPA Substance Registry System: (2E)-3-(2,4-dichlorophenyl)prop-2-en-1-ol(148775-23-9)

Safety Data

• Hazardous Substances Data: 148775-23-9(Hazardous Substances Data)

Usage

Description

(2E)-3-(2,4-dichlorophenyl)prop-2-en-1-ol, also known as 2,4-dichlorobenzyl alcohol, is an organic compound with the molecular formula C9H8Cl2O. It is a colorless to pale yellow liquid with a slightly aromatic odor. (2E)-3-(2,4-dichlorophenyl)prop-2-en-1-ol possesses antimicrobial properties and is valued for its ability to inhibit the growth of bacteria and fungi.

Uses

Used in Pharmaceutical Products:
(2E)-3-(2,4-dichlorophenyl)prop-2-en-1-ol is used as an antiseptic and disinfectant in pharmaceutical products for its ability to inhibit the growth of bacteria and fungi, contributing to the maintenance of hygiene and prevention of infections.
Used in Cosmetic Products:
In the cosmetic industry, (2E)-3-(2,4-dichlorophenyl)prop-2-en-1-ol is used as a preservative to prevent microbial contamination, ensuring the safety and longevity of cosmetic products.
Used in Throat Lozenges and Mouthwashes:
(2E)-3-(2,4-dichlorophenyl)prop-2-en-1-ol is used as an active ingredient in throat lozenges and mouthwashes for its antimicrobial properties, helping to soothe and protect the oral cavity.
Used in Topical Antiseptics:
(2E)-3-(2,4-dichlorophenyl)prop-2-en-1-ol is used in topical antiseptics to prevent infection and promote healing of minor wounds and skin irritations.
Used in Food and Beverage Preservation:
(2E)-3-(2,4-dichlorophenyl)prop-2-en-1-ol is used as a preservative in the food and beverage industry to inhibit the growth of bacteria and fungi, extending the shelf life of products and ensuring their safety for consumption.
Used in Personal and Home Care Products:
(2E)-3-(2,4-dichlorophenyl)prop-2-en-1-ol is used in various personal and home care products for its antimicrobial properties, helping to maintain cleanliness and prevent the spread of bacteria and fungi.

Upstream product

• 82476-04-8 (E)-3-(2,4-dichlorophenyl)acryloyl chloride 
• 1201-99-6 trans-2,4-dichlorocinnamic acid 
• 1504-68-3 (E)-ethyl 3-(2,4-dichlorophenyl)acrylate 
• 70017-27-5 3-(2,4-Dichlorophenyl)propenal 
• 82475-76-1 (E)-3-(2,4-dichlorophenyl)acrylic methyl ester 
• 874-42-0 2,4-dichlorobenzaldeyhde 

Downstream Products

• 869319-47-1 ethyl (3-[1-(2,4-dichlorophenyl)prop-2-en-1-yl]-2-oxocyclohexyl )acetate 
• 24731-17-7 ethyl 2-(2-oxocyclohexyl)acetate 
• 1346682-18-5 2-(2,4-dichlorophenyl)-3-((prop-2-ynyloxy)methyl)oxirane 
• 1346682-64-1 6,8-dichloro-4-o-tolyl-1,3-dihydronaphtho[2,3-c]furan 
• 1346682-12-9 (3-(2,4-dichlorophenyl)oxiran-2-yl)methanol 
• 1346682-38-9 1-(4-(4-chlorophenyl)but-3-yn-2-yloxy)-3-(2,4-dichlorophenyl)propan-2-one 
• 1346682-32-3 1-(2,4-dichlorophenyl)-3-(3-o-tolylprop-2-ynyloxy)propan-2-one 
• 1346682-26-5 1-(but-3-yn-2-yloxy)-3-(2,4-dichlorophenyl)propan-2-one 
• 1346682-25-4 1-(2,4-dichlorophenyl)-3-(prop-2-ynyloxy)propan-2-one 
• 1346682-19-6 2-((but-3-yn-2-yloxy)methyl)-3-(2,4-dichlorophenyl)oxirane 
• 1346682-14-1 (E)-1-(3-(but-3-yn-2-yloxy)prop-1-enyl)-2,4-dichlorobenzene 
• 1346682-13-0 (E)-1-(3-bromoprop-1-enyl)-2,4-dichlorobenzene 
• 86687-46-9 (2R,3R,4S,5R)-2-{4-[(E)-3-(2,4-Dichloro-phenyl)-allylsulfanyl]-pyrazolo[3,4-d]pyrimidin-1-yl}-5-hydroxymethyl-tetrahydro-furan-3,4-diol 
• 77975-44-1 1-Chloro-3-(2,4-dichlorophenyl)prop-2-ene 

Relevant articles and documents

Boron-catalyzed CC functionalization of allyl alcohols

Tris(pentafluorophenyl)borane-catalyzed CC bond functionalization of arylallyl alcohols using donor-acceptor carbenes is presented. The allylic hydroxyl group is found to assist the product formation by neighboring group participation providing a clue towards mechanistic understanding. This method can also be employed to effect homologation of allyl alcohols to homoallyl alcohols. Overall, this metal-free transformation presents a novel disconnection strategy towards carbon-carbon bond scission and formation.

Novel Terminal Bipheny-Based Diapophytoene Desaturases (CrtN) Inhibitors as Anti-MRSA/VISR/LRSA Agents with Reduced hERG Activity

CrtN has been identified as an attractive and druggable target for treating pigmented Staphylococcus aureus infections. More than 100 new compounds were synthesized, which target the overwhelming the defects of the CrtN inhibitor 1. Analogues 23a and 23b demonstrated a significant activity against pigmented S. aureus Newman and 13 MRSA strains (IC50 = 0.02-10.5 nM), along with lower hERG inhibition (IC50 > 30 μM, ～10-fold decrease in comparison with 1). Furthermore, 23a and 23b were confirmed to reduce the staphylococcal load in the kidney and heart in a mouse model with normal treatment deeper than pretreatment ones, comparable even with vancomycin and linezolid. Remarkably, 23a could strongly block the pigment biosynthesis of these nine multidrug-resistant MRSA strains, including excellent activity against LRSA strains and VISA strains in vivo, and all of which demonstrated that 23a has a huge potential against intractable MRSA, VISA, and LRSA issues as a therapeutic drug.

Novel Inhibitors of Staphyloxanthin Virulence Factor in Comparison with Linezolid and Vancomycin versus Methicillin-Resistant, Linezolid-Resistant, and Vancomycin-Intermediate Staphylococcus aureus Infections in Vivo

Our previous work (Wang et al. J. Med. Chem. 2016, 59, 4831-4848) revealed that effective benzocycloalkane-derived staphyloxanthin inhibitors against methicillin-resistant Staphylococcus aureus (S. aureus) infections were accompanied by poor water solubility and high hERG inhibition and dosages (preadministration). In this study, 92 chroman and coumaran derivatives as novel inhibitors have been addressed for overcoming deficiencies above. Derivatives 69 and 105 displayed excellent pigment inhibitory activities and low hERG inhibition, along with improvement of solubility by salt type selection. The broad and significantly potent antibacterial spectra of 69 and 105 were displayed first with normal administration in the livers and hearts in mice against pigmented S. aureus Newman, Mu50 (vancomycin-intermediate S. aureus), and NRS271 (linezolid-resistant S. aureus), compared with linezolid and vancomycin. In summary, both 69 and 105 have the potential to be developed as good antibacterial candidates targeting virulence factors.